VSee Health Reports 2025 Financial Results: Revenue Grows 40% Year-over-Year with a Strong Year End Balance Sheet

VSee Health (Nasdaq:VSEE) reported full-year 2025 results with revenue up 40% to $14,618,184 and a materially stronger balance sheet after debt-to-equity conversions.

Rhea-AI Summary

VSee Health (Nasdaq:VSEE) reported full-year 2025 results with revenue up 40% to $14,618,184 and a materially stronger balance sheet after debt-to-equity conversions. Cash and equivalents rose to $5,266,286 at year-end. The company said operating expenses fell sharply and management expects continued contract-driven growth in 2026.

The company noted multi-year institutional contracts (including a previously announced $10 million per year deal), FedRAMP High approval for VSee Labs, and ongoing telehealth rollouts across multiple states.

Positive

• Revenue +40% to $14,618,184 in 2025
• Cash and equivalents increased to $5,266,286 from $326,115
• Operating expenses declined by 76%
• Signed large multi-year institutional contracts including a $10 million/year deal
• Achieved FedRAMP High status for VSee Labs

Negative

• Majority of 2025 growth concentrated in the second half, creating timing risk for revenue recognition
• Extremely high legal, accounting, and integration expenses tied to the IPO in 2024–2025

Argus Apr 2 session

-5.91% close to close Open Argus

Details

News Market Reaction – VSEE

On Apr 2, the first trading day after this news, VSEE closed 5.91% below the previous close.

Data tracked by StockTitan Argus for the Apr 2 session.

Market Context

On Apr 2, the first trading day after this news, the stock closed 5.9% below the previous close. A n...

Analysis

On Apr 2, the first trading day after this news, the stock closed 5.9% below the previous close. A negative reaction despite this earnings update would have fit prior instances where strong growth headlines did not always translate into immediate gains, such as past quarters that saw revenue acceleration but mixed trading. With shares trading far below the $2.52 52-week high and under the $0.69 200-day moving average, sentiment had remained fragile, leaving the stock vulnerable to profit taking or renewed concern over longer-term profitability.

Key Figures

2025 Revenue: $14,618,184 2024 Revenue: $10,421,352 Revenue Growth: 40% +5 more

2025 Revenue

$14,618,184

Full year 2025 revenue, up 40% YoY

2024 Revenue

$10,421,352

Full year 2024 revenue baseline

Revenue Growth

40%

2025 vs 2024 full-year revenue growth

2025 Gross Margin

$7,355,965

Full year 2025 gross margin dollars

2024 Gross Margin

$7,177,580

Full year 2024 gross margin dollars

OpEx Change

76% decline

Year-over-year operating expense reduction

2025 Cash

$5,266,286

Cash and equivalents at Dec 31, 2025

2024 Cash

$326,115

Cash and equivalents at Dec 31, 2024

Previous Earnings Reports

3 past events · Latest: Oct 17

Same Type 3 events

1. Oct 17

   Q2 2025 results

   24h Move

   -7.9%

   Reported 98% YoY revenue growth and better cash use for H1 2025.

2. Nov 15

   Q3 2024 results

   24h Move

   +2.3%

   Q3 2024 revenue up 131% YoY despite large goodwill impairment-driven net loss.

3. Sep 23

   Q2 2024 update

   24h Move

   +13.8%

   De‑SPAC business update with 33% YoY Q2 revenue growth and new partnerships.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

telehealth, integrated health networks, fedramp high, hhs, +2 more

6 terms

telehealth medical

"a leader in AI-powered telehealth technology and high-acuity virtual care solutions"

Telehealth is the delivery of healthcare services and consultations remotely using video calls, phone, text messaging, or connected devices to monitor and transmit medical information. It matters to investors because it can reshape how patients access care, lower costs, and create new revenue streams or risks for healthcare providers, insurers and technology companies—similar to how online banking changed financial services—while also exposing businesses to reimbursement and regulatory shifts.

integrated health networks medical

"by targeting large IDN's (Integrated Health Networks) in the USA."

A group of hospitals, clinics, doctors and related services that operate together under shared management, records and payment arrangements to coordinate patient care—like a city transit system that links buses, trains and taxis so passengers move more smoothly between stops. Investors care because integrated health networks can lower costs, boost patient retention and create steadier, more predictable revenue through coordinated services and contracts, which can improve profit margins and reduce financial risk.

fedramp high regulatory

"VSee Labs Inc was nominated and approved for Fedramp High status with the Federal Government"

A FedRAMP High designation is a U.S. government security certification for cloud services that handle the most sensitive government data, showing the service meets rigorous controls for confidentiality, integrity and availability. Think of it like a high‑security vault stamp that lets a cloud provider store and process critical government information; for investors, it signals stronger competitive positioning, access to large public-sector contracts and potentially higher compliance costs and liability protection.

hhs regulatory

"This was achieved through its HHS (Health and Human Services) contract awarded"

The U.S. Department of Health and Human Services is the federal agency that shapes national health policy, runs major public-health programs, funds medical research and enforces health-related regulations. Its decisions act like a traffic controller for the health sector—changing rules, funding or approval pathways can speed up or block revenue and market access for hospitals, insurers, drugmakers and medical device companies, so investors watch HHS actions for potential impacts on profits and valuations.

10-k regulatory

"review the complete 10-K filing, which includes detailed financial statements"

A 10-K is a comprehensive annual report a public company files with the U.S. Securities and Exchange Commission that summarizes its business, financial results, risks, legal issues, and management discussion. Investors use it like a company’s detailed yearly report card and instruction manual — it helps reveal how the company makes money, where it might face trouble, and the underlying numbers that support valuation and investment decisions.

View in glossary

management's discussion and analysis financial

"which includes detailed financial statements, Management's Discussion and Analysis, risk factors"

Management's discussion and analysis (MD&A) is a section in a company’s regulatory filings where company leaders explain recent results, trends, risks, and the plans behind their numbers in plain language. It matters to investors because it offers management’s view of what drove performance and what could affect future results — like a coach explaining the game plan and potential challenges — helping investors judge whether the company’s story and strategy are credible.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN JOSE, CA / ACCESS Newswire / April 1, 2026 / VSee Health, Inc. (Nasdaq:VSEE), a leader in AI-powered telehealth technology and high-acuity virtual care solutions, today reported its financial and operational results for the full year ended December 31, 2025. The Company delivered strong top-line growth and meaningful margin improvement while significantly narrowing its net loss.

Key Financial Highlights (Year-over-Year Comparisons)

• Revenue increased 40% to $14,618,184 in 2025 from $10,421,352 in 2024

• Gross margin rose 2% to $7,355,965 from $7,177,580

• Operating expenses declined sharply by 76%

• The Company strengthened its balance sheet through multiple debt to equity conversions

• Cash and liquidity: Cash and cash equivalents increased to $5,266,286 at December 31, 2025, from $326,115 at December 31, 2024

Key Business Highlights

During 2025 VSee Health focused on reducing public expenses associated with the IPO, and growth in its telehealth clinical services group.

The company derived its 40% revenue growth by targeting large IDN's (Integrated Health Networks) in the USA. The team signed several large scale multi-year contracts (one for $10 million per year previously announced) in early and mid 2025. The telehealth revenue for new large healthcare institutional accounts takes several months to begin, as the operations are complex and must be integrated into VSee heath's technology before rolling out services. This is particularly important for our investors to understand that a majority of 2025 growth was in the second half of the year, and subsequently provides solid future growth in those accounts during 2026 as services continue to roll out to as many as 20 states this fiscal year. Management is bullish for 2026 growth as these contracts are continuing to build revenue and adding additional telehealth services.

VSee Health continues to service government accounts such as NASA. In 2025 VSee Labs Inc was nominated and approved for Fedramp High status with the Federal Government as a technology partner. This was achieved through its HHS (Health and Human Services) contract awarded during 2024 and into 2025. VSee continues to pursue several government healthcare related projects in 2026.

VSee Health experienced extremely high legal, accounting, and integration expenses associated with the IPO process in 2024 and 2025. The executive team worked diligently with the Board of Directors to streamline all operations during 2025. VSee believes it can continue to lower its operating costs while growing revenue during 2026.

Outlook and Strategic Position

VSee Health enters 2026 with a fully integrated digital-to-physical care platform, scalable AI telehealth infrastructure, and proven high-acuity clinical delivery. The Company continues to target the rapidly growing hybrid care market while focusing on operational efficiencies, contract renewals, and new enterprise wins. Management remains committed to achieving sustainable profitability and delivering long-term shareholder value.

Investors and interested parties are encouraged to review the complete 10-K filing, which includes detailed financial statements, Management's Discussion and Analysis, risk factors, and business overview, at www.sec.gov or VSeeHealth.com/investors.

About VSee Health, Inc. (Nasdaq: VSEE)

VSee Health is a leader in AI-powered telehealth technology, providing configurable virtual care solutions-including secure video, remote monitoring, AI-enhanced workflows, and seamless EHR integrations-for health systems, government agencies, and large enterprises. Through its iDoc subsidiary, the Company also delivers high-acuity specialty physician services in neurology, tele-radiology, cardiac, and critical care via telehealth.

Forward-Looking Statements

Matters discussed in this news release that are not statements of historical or current facts, including but not limited to those relating to VSee Health's ability to improve healthcare access and provider efficiencies, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause performance or achievements to be materially different from historical results or from any future performance or achievements expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. More information on risk factors relating to VSee Health and its technology and billing services is included from time to time in the "Cautionary Note Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of VSee Health's periodic and current filings with the SEC, which are also made available on VSee Health's website at www.vseehealth.com. Forward-looking statements speak only as of the date they are made, and VSee Health undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, or otherwise. Readers are cautioned not to put undue reliance on forward-looking statements.

Contact:

VSee Health
Anne Chang
media@vsee.com

VSee Investor Contact:
Milton Chen
VSee Health
investor@vsee.com

SOURCE: VSee Health, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did VSee Health (VSEE) revenue grow in 2025 and what was the total amount?

VSee Health reported 40% revenue growth to $14,618,184 in 2025. According to the company, the increase reflected new large institutional telehealth contracts and stronger second-half contributions as integrations ramped.

What drove VSee Health's cash increase to $5,266,286 at December 31, 2025 for VSEE?

Cash rose to $5,266,286 from $326,115 primarily via debt-to-equity conversions and operational improvements. According to the company, balance-sheet actions and cost reductions strengthened liquidity going into 2026.

What is the significance of the $10 million per year contract VSee Health (VSEE) announced?

The $10 million/year contract represents a large multi-year institutional win expected to build recurring revenue. According to the company, services require integration and will contribute more materially as rollouts progress across states in 2026.

Did VSee Health (VSEE) report margin or expense improvements in 2025?

Yes. The company reported operating expenses declined by 76%, improving margins and narrowing net loss. According to the company, cost reductions largely reflect streamlined public-company and integration expenses.

What government credentials did VSee Labs secure and how does that affect VSee Health (VSEE)?

VSee Labs achieved FedRAMP High approval as a federal technology partner. According to the company, this supports government healthcare work (including HHS and NASA) and may enable additional federal contract opportunities in 2026.